Penserra Capital Management LLC grew its holdings in Eli Lilly And Co (NYSE:LLY) by 372.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,673 shares of the company’s stock after buying an additional 14,723 shares during the quarter. Penserra Capital Management LLC’s holdings in Eli Lilly And Co were worth $2,003,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Eli Lilly And Co during the 2nd quarter worth about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Eli Lilly And Co during the 2nd quarter worth about $114,000. Legacy Advisors LLC increased its position in shares of Eli Lilly And Co by 118.0% during the 2nd quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares in the last quarter. Fort L.P. acquired a new stake in shares of Eli Lilly And Co during the 2nd quarter worth about $121,000. Finally, Welch Group LLC acquired a new stake in shares of Eli Lilly And Co during the 3rd quarter worth about $123,000. Institutional investors own 76.17% of the company’s stock.
LLY opened at $112.21 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $116.23 billion, a price-to-earnings ratio of 26.22, a P/E/G ratio of 1.75 and a beta of 0.29. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.05 EPS. As a group, equities research analysts forecast that Eli Lilly And Co will post 5.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is presently 52.57%.
A number of brokerages recently issued reports on LLY. Guggenheim began coverage on shares of Eli Lilly And Co in a research report on Monday, October 8th. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 9th. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Monday, October 8th. BMO Capital Markets upgraded shares of Eli Lilly And Co from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $107.00 to $130.00 in a research report on Thursday, October 4th. Finally, JPMorgan Chase & Co. set a $123.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Friday, October 5th. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.19.
In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the sale, the insider now owns 3,530 shares in the company, valued at approximately $372,662.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the firm’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. Insiders sold a total of 1,881,684 shares of company stock valued at $133,274,076 in the last 90 days. Corporate insiders own 0.11% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Preferred Stock
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.